Quick Answer
SANGAMO THERAPEUTICS, INC reported Revenue (ASC 606) of $39.55 million for fiscal year 2025.
SANGAMO THERAPEUTICS, INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $39.55M | -31.6% |
| 2024 | $57.80M | -67.2% |
| 2023 | $176.23M | +58.3% |
| 2022 | $111.30M | +0.5% |
| 2021 | $110.70M | -6.3% |
| 2020 | $118.19M | +15.4% |
| 2019 | $102.43M | +21.3% |
| 2018 | $84.45M | +131.0% |
| 2017 | $36.57M | +88.6% |
| 2016 | $19.39M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $581.0K | -98.8% | -96.8% |
| June 30, 2025 | $18.31M | +5042.1% | +184.4% |
| March 31, 2025 | $6.44M | +1238.3% | -87.0% |
| September 30, 2024 | $49.41M | +425.8% | +13779.8% |
| June 30, 2024 | $356.0K | -94.8% | -26.0% |
| March 31, 2024 | $481.0K | -99.7% | -94.9% |
| September 30, 2023 | $9.40M | -64.5% | +37.5% |
| June 30, 2023 | $6.83M | -76.7% | -95.7% |
- SANGAMO THERAPEUTICS, INC showed a decrease of -31.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, SANGAMO THERAPEUTICS, INC’s revenue (asc 606) has grown by 104.0% (from $19.39 million to $39.55 million).
- The most recent figure is from SANGAMO THERAPEUTICS, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: